What Will Redefine Pathology in 2026?
Industry leaders outline how computational modeling and large-scale sequencing will reshape discovery, diagnostics, and clinical development in 2026 and beyond
By
Jessica Allerton
January 14, 2026
Clinical Scorecard: What Will Redefine Pathology in 2026?
At a Glance
Category Detail
Condition Pathology and Laboratory Medicine Key Mechanisms Advancements in AI, long-read sequencing, and inclusive genomics. Target Population Global population with a focus on genetic diversity. Care Setting Clinical research and development environments.
Key Highlights
Increased adoption of AI in R&D for hypothesis generation and experiment design. Long-read sequencing to address complex repeat expansion disorders. Emergence of population-specific genomic projects worldwide. Integration of biological modeling in early discovery processes. Mainstream use of digital twins in clinical development. Guideline-Based Recommendations
Diagnosis
Utilize long-read sequencing for complex genetic disorders. Management
Adopt AI-guided platforms for target identification in biologics. Monitoring & Follow-up
Implement digital twins for optimizing clinical trial protocols. Risks
Ensure rigorous validation and ethical governance of AI tools. Patient & Prescribing Data
Individuals with genetic disorders and those participating in clinical trials.
Focus on personalized medicine through inclusive genomic data.
Clinical Best Practices
Integrate AI tools into R&D workflows for enhanced efficiency. Promote collaboration among regulators, sponsors, and technology partners. Utilize biological modeling to improve candidate selection in drug discovery. Related Resources & Content
